- News Home
5 December 2013 11:26 am ,
Vol. 342 ,
An animal rights group known as the Nonhuman Rights Project filed lawsuits in three New York courts this week in an...
Researchers have been hot on the trail of the elusive Denisovans, a type of ancient human known only by their DNA and...
Thousands of scientists in the Russian Academy of Sciences (RAS) are about to lose their jobs as a result of the...
Dyslexia, a learning disability that hinders reading, hasn't been associated with deficits in vision, hearing, or...
Exotic, elusive, and dangerous, snakes have fascinated humankind for millennia. They can be hard to find, yet their...
Researchers have sequenced and analyzed the first two snake genomes, which represent two evolutionary extremes. The...
Snake venoms are remarkably complex mixtures that can stun or kill prey within minutes. But more and more researchers...
At age 30, Dutch biologist Freek Vonk has built up a respectable career as a snake scientist. But in his home country,...
- 5 December 2013 11:26 am , Vol. 342 , #6163
- About Us
Lasker Award Rekindles Debate Over Artemisinin's Discovery
29 September 2011 3:26 pm
The Lasker Foundation's first ever award to a Chinese scientist working on the mainland has reignited a 30-year controversy over whether one person should be recognized for developing a powerful antimalarial drug that was the product of a massive government project during China's Cultural Revolution. Last Friday in New York City, the foundation presented Tu Youyou, an 80-year-old phytochemist at the China Academy of Traditional Chinese Medicine, with the 2011 Lasker-DeBakey Clinical Medical Research Award for "the discovery of artemisinin, a drug therapy for malaria that has saved millions of lives across the globe, especially in the developing world." But some Chinese scientists disagree with the citation, particularly its exclusive focus on Tu.
Wu Yulin, a retired chemist at the Chinese Academy of Sciences's Institute of Organic Chemistry who helped determine the chemical structure of artemisinin, wrote in response to an inquiry from ScienceInsider that Tu "made contributions to the discovery of the compound" but did not make significant contributions after that. Critics of the Lasker citation emphasize that development of the artemisinin-based combination therapy used today resulted from a scientific relay race that went through many stages. In comments on Web postings and in an independent newspaper, they argue that more than one person deserves to be cited for the achievement.
Tu's proponents argue, however, that her discovery stands out. Two supporters—Louis Miller, chief of Malaria Cell Biology at the National Institutes of Health in Bethesda, Maryland, and colleague Xinzhuan Su, also at NIH—described Tu's contributions in a 16 September Cell article, writing that they have "no doubt that the major credit must go to Youyou." Su says their conclusion was backed by classified documents shown to them by Tu and officials at her institute.
Rao Yi, a neuroscientist at Peking University in Beijing, takes a more nuanced stand in support of Tu. Rao and his colleagues say they have seen a much larger set of classified and internal documents archived at institutions that were involved in artemisinin research and interviewed many of the major players. Rao says, "Although we agree with Miller and Su that Youyou should be recognized as a representative, we find they went too far in reaching conclusions that are not supported by available sources and in attributing credits based on claims that are at least controversial if not wrong." Rao included some of their findings in an article he posted online. He says: "Our article is very specific about clarifying the role of Tu Youyou, and we came to the conclusion that Tu is a representative of the project. We clearly mentioned others such as [contemporary artemisinin researchers] Yu Yagang and Zhong Yurong. We did note that the roles of others need to be further studied and established."
The search that led to artemisinin began in the 1960s when the North Vietnamese government asked China for help in finding a cure for drug-resistant malaria, which was decimating troops in the jungles of Indochina. Under Mao Zedong's instruction, China launched a secret effort at the height of the Cultural Revolution in 1967. Code-named Project 523, it mobilized more than 500 researchers from some 60 organizations across several military and civilian agencies.
Project 523 planned a three-pronged attack on drug-resistant malaria: research and develop new drugs the Western way, screen traditional medicine and folk remedies to search for a Chinese therapy, and find ways to prevent malaria infection in the first place. Tu's institute, the Institute of Chinese Materia Medica, was assigned to work on the second approach. According to research by Rao's group, Yu Yagang, who worked at the same institute as Tu, analyzed a 1965 compilation of traditional remedies for malaria statistically and found qinghao (green-blue wormwood) was one of the ingredients used most often. Yu then worked with another researcher from the Academy of Military Medical Sciences to test a crude extract of qinghao on a rodent model of malaria, finding that the extract killed parasites with 60% to 80% potency. Yu reported the results to Tu, the group leader. Yu soon was reassigned to an even larger effort—searching for a treatment for bronchitis, from which Mao suffered. Tu then asked others in the group to repeat Yu's experiment, but they couldn't obtain extracts with consistent potency.
Tu describes her work in some detail in an essay in the October issue of Nature Medicine. She suspected that extraction at high temperature destroyed the active ingredient of qinghao. She went back to the traditional medicine book and, after reading about a preparation that called for soaking qinghao with cold water, proposed using a low boiling point solvent to extract the active chemical. This insight is considered a breakthrough step toward the discovery of artemisinin by her supporters. Tu's detractors, however, point out that using ether and other low boiling point solvents to extract active ingredients from plants is standard phytochemistry.
Li Ying, a retired chemist at the Chinese Academy of Sciences Institute of Materia Medica in Shanghai, who worked on the synthesis of artemisinin derivatives, wrote in an article in 2008 that Tu's method of extraction and purification yielded crystals containing artemisinin mixed with other chemicals, giving rise to toxicity in clinical trials. At roughly this time, Wei Zhenxing of the Shandong Institute of Pharmacology and Luo Zeyuan of the Yunnan Institute of Pharmacology, after hearing about Tu's breakthrough, each independently derived antimalarial chemicals from local herbs called huang hua hao or yellow-flower wormwood (Artemisia annua). Several species were used traditionally as medicinal qinghao, but only A. annua eventually proved to contain a sufficient amount of artemisinin. The Yunnan group also found the best cultivated source of A. annua in another province. Using this source, they were able to produce pure artemisinin in large quantities, speeding up drug research and development. Tu's group also adopted the Yunnan method.
Meanwhile, researchers working in Shanghai from 1973 to 1975 found that artemisinin has a novel and unusual structure, a so-called peroxide bridge. Artemisinin is the only natural compound known to have this structure. It is key to its antimalarial property and makes artemisinin-based drugs entirely different from those derived from quinine, such as chloroquine, to which malarial parasites have become resistant. Li Ying's group in Shanghai synthesized artemisinin derivatives that were more potent at killing malaria parasites and had more desirable chemical properties (such as solubility in water), making them better drug candidates than natural artemisinin. They are the basis of therapy used today. It was only after secrecy rules were lifted in 1977 that research papers from Project 523 began to come out.
After the Lasker Award ceremony, Tu seemed eager to mollify the critics, telling Xinhua News Agency, "I think the honor not only belongs to me but also to all Chinese scientists."
Because the Lasker Award is often seen as a precursor to the Nobel Prize, the Chinese media are abuzz with anticipation. But some worry that the disagreement over credit might give the Nobel committee pause. Rao says that if he had to choose three scientists—the limit for the Nobel—then he would pick either Yu Yagang, Tu Youyou, and Zhong Yurong for the discovery of artemisinin; or Tu Youyou, Luo Zeyuan, and Li Ying for the early work on artemisinin that led to the drug therapy.